Joshua Brumm
2020 - Dyne Therapeutics
In 2020, Joshua Brumm earned a total compensation of $11.9M as President and Chief Executive Officer at Dyne Therapeutics, a 4,180% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $299,877 |
|---|---|
| Option Awards | $7,944,295 |
| Salary | $482,667 |
| Stock Awards | $3,134,366 |
| Other | $6,900 |
| Total | $11,868,105 |
Brumm received $7.9M in option awards, accounting for 67% of the total pay in 2020.
Brumm also received $299.9K in non-equity incentive plan, $482.7K in salary, $3.1M in stock awards and $6.9K in other compensation.
Rankings
In 2020, Joshua Brumm's compensation ranked 631st out of 13,090 executives tracked by ExecPay. In other words, Brumm earned more than 95.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 631 out of 13,090 | 95th |
Division Manufacturing | 216 out of 5,621 | 96th |
Major group Chemicals And Allied Products | 69 out of 2,254 | 97th |
Industry group Drugs | 59 out of 1,954 | 97th |
Industry Pharmaceutical Preparations | 44 out of 1,459 | 97th |
Source: SEC filing on April 14, 2021.
Brumm's colleagues
We found two more compensation records of executives who worked with Joshua Brumm at Dyne Therapeutics in 2020.
News
Dyne Therapeutics CEO Joshua Brumm's 2022 pay rises 6% to $4.3M
April 7, 2023
Dyne Therapeutics CEO Joshua Brumm's 2021 pay falls 66% to $4.1M
April 22, 2022
Dyne Therapeutics CEO Joshua Brumm's 2020 pay jumps 981% to $12M
April 14, 2021
Kaleido Biosciences CEO Alison Lawton's 2019 pay falls 57% to $2.9M
May 8, 2020